CN115300508A - 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂 - Google Patents

包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂 Download PDF

Info

Publication number
CN115300508A
CN115300508A CN202210843681.2A CN202210843681A CN115300508A CN 115300508 A CN115300508 A CN 115300508A CN 202210843681 A CN202210843681 A CN 202210843681A CN 115300508 A CN115300508 A CN 115300508A
Authority
CN
China
Prior art keywords
montelukast
combination
pharmaceutically acceptable
inflammation
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210843681.2A
Other languages
English (en)
Chinese (zh)
Inventor
B·I·塞缪森
顾铭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Etia Shanghai Pharmaceutical Co ltd
Original Assignee
Etia Shanghai Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etia Shanghai Pharmaceutical Co ltd filed Critical Etia Shanghai Pharmaceutical Co ltd
Publication of CN115300508A publication Critical patent/CN115300508A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202210843681.2A 2017-07-05 2018-07-04 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂 Pending CN115300508A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2017091819 2017-07-05
CNPCT/CN2017/091819 2017-07-05
CN2018087058 2018-05-16
CNPCT/CN2018/087058 2018-05-16
CN201880002883.6A CN110312513B (zh) 2017-07-05 2018-07-04 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
PCT/CN2018/094441 WO2019007356A1 (en) 2017-07-05 2018-07-04 TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880002883.6A Division CN110312513B (zh) 2017-07-05 2018-07-04 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂

Publications (1)

Publication Number Publication Date
CN115300508A true CN115300508A (zh) 2022-11-08

Family

ID=64949737

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880002883.6A Active CN110312513B (zh) 2017-07-05 2018-07-04 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
CN202210843681.2A Pending CN115300508A (zh) 2017-07-05 2018-07-04 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
CN202110903665.3A Pending CN113491696A (zh) 2017-07-05 2018-07-04 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201880002883.6A Active CN110312513B (zh) 2017-07-05 2018-07-04 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110903665.3A Pending CN113491696A (zh) 2017-07-05 2018-07-04 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂

Country Status (13)

Country Link
US (3) US11672792B2 (enExample)
EP (1) EP3648767A4 (enExample)
JP (1) JP7288404B2 (enExample)
KR (1) KR102785243B1 (enExample)
CN (3) CN110312513B (enExample)
AU (1) AU2018295944B2 (enExample)
CA (1) CA3068818A1 (enExample)
MA (1) MA52924A (enExample)
MX (1) MX2020000029A (enExample)
MY (1) MY201703A (enExample)
SG (1) SG11201911841PA (enExample)
TW (1) TWI874298B (enExample)
WO (1) WO2019007356A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491696A (zh) * 2017-07-05 2021-10-12 江阴优培尔康药业有限公司 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3678705T1 (sl) 2018-09-14 2023-10-30 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. Konjugati montelukasta in peptidov
MA54707A (fr) * 2019-01-10 2021-11-17 Jiangyin Mucocare Pharmaceutical Co Ltd Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes
MX2022003057A (es) * 2019-09-14 2022-06-16 Jiangyin Usun Pharmaceutical Co Ltd Nuevos peptidos.
CN114929259A (zh) * 2019-12-02 2022-08-19 艾缇亚(上海)制药有限公司 新型多功能寡肽
CN114929283A (zh) * 2019-12-02 2022-08-19 艾缇亚(上海)制药有限公司 肽和多糖的新缀合物
BR112022015199A2 (pt) 2020-02-03 2022-10-11 Taro Pharma Ind Formulações tópicas de montelucaste
US12233055B2 (en) 2020-02-03 2025-02-25 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
EP4228641A1 (en) 2020-10-13 2023-08-23 Diomed Developments Limited Gel formulations comprising montelukast
CN114588267A (zh) * 2020-12-04 2022-06-07 江苏恒瑞医药股份有限公司 一种含酰胺类局部麻醉药的药物组合物
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
TW202337464A (zh) * 2021-08-06 2023-10-01 大陸商安利提沙（上海）製藥有限公司 免疫不全病症的新治療
CN116421547A (zh) * 2023-03-09 2023-07-14 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213989C (en) * 1995-12-28 2007-05-29 Yoshitomi Pharmaceutical Industries Ltd. External preparation for topical administration
US20030207932A1 (en) 2002-05-03 2003-11-06 Morris Mann Compositions that prevent post-traumatic hyperpigmentation and methods related thereto
ATE529125T1 (de) * 2003-08-07 2011-11-15 Healor Ltd Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
US6987170B1 (en) * 2004-08-09 2006-01-17 Battelle Energy Alliance, Llc Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis
WO2007126865A2 (en) * 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
CN1961867A (zh) 2006-11-16 2007-05-16 徐英权 孟鲁司特钠的颗粒剂型
WO2008106081A1 (en) * 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation
WO2008105803A1 (en) 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and uses thereof
WO2009137555A1 (en) 2008-05-06 2009-11-12 Schlesinger S Larry Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
GB0915319D0 (en) 2009-09-03 2009-10-07 Sharma Anant Combination medicament
CN101773503A (zh) 2010-01-12 2010-07-14 北京华禧联合科技发展有限公司 一种白三烯拮抗剂和抗组胺药组合物
CA2802853C (en) 2010-06-16 2016-07-26 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
CN102895661A (zh) * 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
JP6200432B2 (ja) 2011-12-26 2017-09-20 エスケー ケミカルズ カンパニー リミテッド モンテルカストまたはその薬学的に許容可能な塩を含む経口投与用フィルム
CN103239450B (zh) 2012-02-07 2014-11-26 齐鲁制药有限公司 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法
EP3308835B1 (en) * 2013-03-13 2020-01-01 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CN103655497B (zh) 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
WO2016021599A1 (ja) * 2014-08-04 2016-02-11 日東電工株式会社 液性免疫誘導促進用組成物及びワクチン医薬組成物
CN105769825A (zh) 2014-12-24 2016-07-20 广州朗圣药业有限公司 一种孟鲁司特钠的口腔膜剂及其制备方法
CN105878215A (zh) 2014-12-31 2016-08-24 天津康鸿医药科技发展有限公司 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途
KR101892340B1 (ko) * 2015-03-13 2018-08-27 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
CN104784157B (zh) 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂
WO2017011983A1 (zh) * 2015-07-20 2017-01-26 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白用于皮肤和皮肤附属器官的防护
BR112018000953A2 (pt) 2015-07-20 2018-09-11 Bengt I. Samuelsson Institute Of Life Science Research produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele
WO2017147067A1 (en) * 2016-02-22 2017-08-31 Board Of Regents, The University Of Texas System Antimicrobial compositions and uses thereof
US10548837B1 (en) 2016-05-04 2020-02-04 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis
EP3648767A4 (en) * 2017-07-05 2021-04-28 Jiangyin Mucocare Pharmaceutical Co., Ltd TOPICAL FORMULATIONS WITH MONTELUKAST AND COMBINATIONS WITH SHELL ADHESION PROTEINS
JP7742226B2 (ja) * 2018-05-28 2025-09-19 ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド 新たな医薬品使用
SI3678705T1 (sl) * 2018-09-14 2023-10-30 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. Konjugati montelukasta in peptidov
MA54707A (fr) * 2019-01-10 2021-11-17 Jiangyin Mucocare Pharmaceutical Co Ltd Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491696A (zh) * 2017-07-05 2021-10-12 江阴优培尔康药业有限公司 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂

Also Published As

Publication number Publication date
AU2018295944B2 (en) 2023-12-14
TW201919633A (zh) 2019-06-01
KR102785243B1 (ko) 2025-03-26
CN110312513A (zh) 2019-10-08
MX2020000029A (es) 2020-08-06
KR20200039677A (ko) 2020-04-16
CN113491696A (zh) 2021-10-12
TWI874298B (zh) 2025-03-01
EP3648767A1 (en) 2020-05-13
CN110312513B (zh) 2022-07-08
AU2018295944A1 (en) 2020-02-20
MY201703A (en) 2024-03-13
SG11201911841PA (en) 2020-01-30
CA3068818A1 (en) 2019-01-10
US20230404992A1 (en) 2023-12-21
MA52924A (fr) 2021-04-28
US20250302818A1 (en) 2025-10-02
US20210145819A1 (en) 2021-05-20
JP2020527134A (ja) 2020-09-03
JP7288404B2 (ja) 2023-06-07
US11672792B2 (en) 2023-06-13
EP3648767A4 (en) 2021-04-28
WO2019007356A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
US20250302818A1 (en) Topical formulations comprising montelukast and combinations with mussel adhesive proteins
JP7198785B2 (ja) ペプチドの抗炎症的使用
JP7742226B2 (ja) 新たな医薬品使用
TWI875712B (zh) 孟魯司特與肽的新共軛物
KR20210114962A (ko) 류코트리엔 수용체 길항제를 함유하는 신규 제제
TWI901567B (zh) 胜肽之抗發炎用途
HK40082364A (en) Topical formulations comprising combinations of montelukast and mussel adhesion proteins
HK40058104A (en) Topical formulations comprising combinations of montelukast and mussel adhesion proteins
HK40014584B (en) Topical formulations comprising montelukast and combinations with mussel adhesive proteins
HK40014584A (en) Topical formulations comprising montelukast and combinations with mussel adhesive proteins
HK40011773B (zh) 肽的抗炎用途
HK40011773A (en) Anti-inflammatory use of peptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20221108

Assignee: Shanghai Shangyao Innovative Pharmaceutical Technology Co.,Ltd.

Assignor: Etia (Shanghai) Pharmaceutical Co.,Ltd.

Contract record no.: X2022990000923

Denomination of invention: Topical preparation containing a combination of montelukast and mussel adhesion protein

License type: Exclusive License

Record date: 20221110

EE01 Entry into force of recordation of patent licensing contract
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082364

Country of ref document: HK